berberine has been researched along with Helicobacter Infections in 10 studies
Helicobacter Infections: Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Berberine (BBR) is an isoquinoline alkaloid derived from various medicinal herbs." | 5.48 | Berberine demonstrates anti-inflammatory properties in Helicobacter pylori-infected mice with chronic gastritis by attenuating the Th17 response triggered by the B cell-activating factor. ( Dang, Z; Jia, Y; Li, X; Wu, X, 2018) |
| " The secondary outcomes were symptom improvement rate, patient compliance, and incidence of adverse events." | 3.30 | Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial. ( Chen, S; Dong, Q; Liu, Y; Shen, W; Shi, Y, 2023) |
| "Berberine (BBR) is an isoquinoline alkaloid derived from various medicinal herbs." | 1.48 | Berberine demonstrates anti-inflammatory properties in Helicobacter pylori-infected mice with chronic gastritis by attenuating the Th17 response triggered by the B cell-activating factor. ( Dang, Z; Jia, Y; Li, X; Wu, X, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 7 (70.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Q | 1 |
| Tang, J | 1 |
| Chen, S | 2 |
| Hu, S | 1 |
| Shen, C | 1 |
| Xiang, J | 1 |
| Chen, N | 1 |
| Wang, J | 1 |
| Ma, X | 1 |
| Zhang, Y | 1 |
| Zeng, J | 1 |
| Shen, W | 1 |
| Liu, Y | 1 |
| Dong, Q | 1 |
| Shi, Y | 1 |
| Wu, H | 1 |
| Xie, X | 1 |
| Tang, Q | 1 |
| Huang, T | 1 |
| Tang, X | 1 |
| Jiao, B | 1 |
| Wang, R | 3 |
| Zhu, X | 1 |
| Ye, X | 1 |
| Ma, H | 1 |
| Li, X | 2 |
| Yang, T | 2 |
| Zhang, J | 3 |
| Bao, C | 1 |
| Li, R | 1 |
| Chen, X | 3 |
| Wu, S | 2 |
| Wen, J | 1 |
| Wei, S | 1 |
| Li, H | 1 |
| Cai, H | 1 |
| Yang, X | 3 |
| Zhao, Y | 2 |
| Han, C | 1 |
| Lu, WQ | 1 |
| Wang, N | 1 |
| Wu, SR | 1 |
| Wang, YX | 1 |
| Ma, JP | 1 |
| Wang, JH | 1 |
| Hao, C | 1 |
| Yuan, DH | 1 |
| Liu, N | 1 |
| Shi, YQ | 2 |
| Shen, Y | 1 |
| Zou, Y | 1 |
| Li, P | 1 |
| Rao, Y | 1 |
| Sun, Y | 1 |
| Hu, H | 1 |
| Liu, H | 1 |
| Wang, L | 1 |
| Li, J | 1 |
| Zhang, D | 1 |
| Ke, L | 1 |
| Ni, Z | 1 |
| Chen, Y | 1 |
| Zhang, LH | 1 |
| Zhu, SH | 1 |
| Li, CJ | 1 |
| Shang, L | 1 |
| Liang, J | 1 |
| Wu, X | 1 |
| Dang, Z | 1 |
| Jia, Y | 1 |
| Lin, YH | 1 |
| Lin, JH | 1 |
| Chou, SC | 1 |
| Chang, SJ | 1 |
| Chung, CC | 1 |
| Chen, YS | 1 |
| Chang, CH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bismuth Quadruple Therapy in Helicobacter Pylori Rescue Therapy: A Multicenter Randomized Non-Inferiority Trial of Different Tetracycline Doses and Frequencies.[NCT05802888] | Phase 4 | 260 participants (Anticipated) | Interventional | 2023-03-12 | Recruiting | ||
| Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy[NCT03609892] | Phase 4 | 658 participants (Actual) | Interventional | 2018-08-01 | Completed | ||
| Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment: A Multicenter Randomized Clinical Trial of Different Tetracycline Doses and Frequencies.[NCT05431075] | Phase 4 | 407 participants (Anticipated) | Interventional | 2022-07-31 | Not yet recruiting | ||
| Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy: A Multicenter Randomized Non-Inferiority Trial of Different Tetracycline Doses and Frequencies.[NCT05432115] | Phase 4 | 407 participants (Anticipated) | Interventional | 2022-06-25 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for berberine and Helicobacter Infections
| Article | Year |
|---|---|
Berberine for gastric cancer prevention and treatment: Multi-step actions on the Correa's cascade underlie its therapeutic effects.
Topics: Anti-Bacterial Agents; Berberine; Carcinogenesis; Cytokines; Gastritis; Gastritis, Atrophic; Helicob | 2022 |
3 trials available for berberine and Helicobacter Infections
6 other studies available for berberine and Helicobacter Infections
| Article | Year |
|---|---|
Epiberberine inhibits Helicobacter pylori and reduces host apoptosis and inflammatory damage by down-regulating urease expression.
Topics: Animals; Berberine; Helicobacter Infections; Helicobacter pylori; Inflammation; Molecular Docking Si | 2024 |
Mechanism of berberine in treating Helicobacter pylori induced chronic atrophic gastritis through IRF8-IFN-γ signaling axis suppressing.
Topics: Animals; Anti-Inflammatory Agents; Berberine; Cell Line; Cell Proliferation; Cell Survival; Chemokin | 2020 |
Antibacterial self-assembled nanodrugs composed of berberine derivatives and rhamnolipids against Helicobacter pylori.
Topics: Animals; Anti-Bacterial Agents; Berberine; Biofilms; Glycolipids; Helicobacter Infections; Helicobac | 2020 |
Berberine regulates macrophage polarization through IL-4-STAT6 signaling pathway in Helicobacter pylori-induced chronic atrophic gastritis.
Topics: Animals; Berberine; Gastritis, Atrophic; Gene Expression Regulation; Helicobacter Infections; Helico | 2021 |
Berberine demonstrates anti-inflammatory properties in Helicobacter pylori-infected mice with chronic gastritis by attenuating the Th17 response triggered by the B cell-activating factor.
Topics: Animals; Anti-Inflammatory Agents; B-Cell Activating Factor; Berberine; Cells, Cultured; Chronic Dis | 2018 |
Berberine-loaded targeted nanoparticles as specific Helicobacter pylori eradication therapy: in vitro and in vivo study.
Topics: Animals; Berberine; Chitosan; Drug Delivery Systems; Fucose; Helicobacter Infections; Helicobacter p | 2015 |